FDA warning 30 telehealth sites over compounded GLP-1 marketing
Posted by tiredmira in Weight Loss & Metabolic - 1 points, 0 comments.
PharmTech has a piece on the FDA sending out 30 warning letters to telehealth companies for shady marketing around compounded semaglutide and tirzepatide. Basically the feds are cracking down on the telehealth GLP-1 space, which honestly feels overdue.
What gets me is how many of these places were running ads that made compounded stuff sound basically identical to the brand name versions. If you have ever been tempted by a $199 monthly "same as Ozempic" pitch, this is why it pays to slow down and read what is actually in the vial. I get that brand pricing is brutal, but marketing compounds as interchangeable with the real thing is just not it.
Curious if anyone here has actually seen the warning letters change anything on the telehealth side, or if it just pushes the marketing language around. Have any of you switched providers because of stuff like this?
Community discussion - research and educational context only. Not medical advice.